AIM ImmunoTech Reports CEO Article on Ampligen's Ebola Potential

What Happened
On August 11, 2026 AIM ImmunoTech (AIM) filed a Form 8-K (Item 7.01) to furnish an article published that day by Breaking Defense. The piece, titled “Biodefense is force protection: Ready today, prepared for tomorrow,” was authored by Thomas K. Equels, AIM’s Chief Executive Officer, and discusses the company’s drug Ampligen (rintatolimod) and its potential role as a broad‑spectrum early‑onset and/or prophylactic antiviral therapeutic for Ebola virus disease and in the treatment of COVID‑19 and related viruses. The article is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: August 11, 2026; Item: 7.01 (Regulation FD Disclosure).
• Author: Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech.
• Article title: “Biodefense is force protection: Ready today, prepared for tomorrow,” published on BreakingDefense.com and furnished as Exhibit 99.1.
• Subject: Discussion of Ampligen (rintatolimod) as a potential broad‑spectrum early‑onset/prophylactic antiviral for Ebola and commentary on its history and potential for COVID‑19 and related viruses. (Cover page iXBRL Exhibit 104 also included.)

Why It Matters
The 8‑K furnishes (but does not file as a formal disclosure of new clinical data) a CEO‑authored article highlighting Ampligen’s potential uses in biodefense and antiviral treatment. For investors, this is a public communication by management that may shape awareness and sentiment but does not by itself provide new financial results, regulatory approvals, or clinical trial outcomes. Reviewers should treat the article as management commentary disclosed under Regulation FD rather than as a report of definitive clinical or regulatory developments.